---
title: "Headache"
order: 5
category: "Neurology"
---

# Headache

## Overview

Headache is one of the most common neurological complaints, affecting virtually everyone at some point in their lives. It can range from mild, occasional discomfort to severe, debilitating pain that significantly impacts quality of life. Headaches are classified as primary (no underlying structural cause) or secondary (due to an underlying condition). Understanding the different types and their management is crucial for effective treatment.

### Epidemiology
- **Prevalence**: >90% of people experience headache in their lifetime
- **Primary headaches**: Account for >95% of all headaches
- **Gender differences**: Migraine more common in women (3:1 ratio)
- **Economic burden**: Significant healthcare costs and lost productivity

### Classification
- **Primary headaches**: Migraine, tension-type, cluster, other
- **Secondary headaches**: Due to underlying pathology
- **Cranial neuralgias**: Trigeminal neuralgia, occipital neuralgia
- **Other headache disorders**: Medication overuse, post-traumatic

## Pathophysiology

### Pain-Sensitive Structures
- **Intracranial**: Blood vessels, dura mater, cranial nerves V, VII, IX, X
- **Extracranial**: Muscles, skin, blood vessels, periosteum
- **Insensitive structures**: Brain parenchyma, skull, most dura

### Neural Pathways
- **Trigeminal system**: Primary afferent pathway for head pain
- **Trigeminovascular system**: Trigeminal innervation of blood vessels
- **Central sensitization**: Enhanced pain processing in CNS
- **Descending modulation**: Brainstem pain control systems

### Neurotransmitters
- **Serotonin (5-HT)**: Central role in migraine pathophysiology
- **CGRP**: Calcitonin gene-related peptide, key migraine mediator
- **Substance P**: Pain transmission and neurogenic inflammation
- **Dopamine**: Involved in migraine symptoms and medication effects

## Migraine

### Overview
- **Prevalence**: 12% of population, 18% of women, 6% of men
- **Pathophysiology**: Complex neurovascular disorder
- **Genetics**: Strong familial component, polygenic inheritance
- **Triggers**: Identifiable in many patients

### Pathophysiology

#### Trigeminovascular Theory
- **Trigeminovascular activation**: Release of vasoactive peptides
- **Neurogenic inflammation**: Dilation and plasma extravasation
- **Central sensitization**: Enhanced pain processing
- **Cortical spreading depression**: Migraine aura mechanism

#### Brainstem Dysfunction
- **Migraine generator**: Brainstem nuclei activation
- **Hypothalamic involvement**: Premonitory symptoms
- **Trigeminal nucleus**: Central pain processing
- **Descending modulation**: Altered pain control

### Clinical Presentation

#### Migraine Phases
1. **Premonitory phase**: Hours to days before headache
   - **Symptoms**: Mood changes, food cravings, fatigue, neck stiffness
   - **Duration**: 2-48 hours
   - **Frequency**: 60-70% of migraineurs

2. **Aura phase**: Neurological symptoms (in 25% of patients)
   - **Visual aura**: Scintillating scotoma, fortification spectra
   - **Sensory aura**: Numbness, tingling, typically unilateral
   - **Speech aura**: Dysphasia, speech difficulties
   - **Motor aura**: Weakness (hemiplegic migraine)
   - **Duration**: 5-60 minutes, typically 20-30 minutes

3. **Headache phase**: The main pain episode
   - **Quality**: Throbbing, pulsating
   - **Location**: Unilateral (but can be bilateral)
   - **Intensity**: Moderate to severe
   - **Duration**: 4-72 hours if untreated
   - **Associated symptoms**: Nausea, vomiting, photophobia, phonophobia

4. **Resolution phase**: Recovery period
   - **Symptoms**: Fatigue, mood changes, cognitive difficulties
   - **Duration**: Hours to days
   - **"Hangover" effect**: Common post-ictal phenomenon

#### Migraine Subtypes

##### Migraine Without Aura (75%)
- **Criteria**: Recurrent attacks, 4-72 hours, unilateral, pulsating, moderate-severe intensity
- **Associated symptoms**: Nausea/vomiting, photophobia/phonophobia
- **Aggravation**: Physical activity

##### Migraine With Aura (25%)
- **Visual aura**: Most common type
- **Sensory aura**: Unilateral numbness/tingling
- **Speech aura**: Language disturbances
- **Typical duration**: Aura 5-60 minutes, headache follows within 1 hour

##### Chronic Migraine
- **Definition**: ≥15 headache days per month, ≥8 with migraine features
- **Duration**: >3 months
- **Risk factors**: Medication overuse, obesity, sleep disorders
- **Impact**: Significant disability and reduced quality of life

##### Status Migrainosus
- **Definition**: Migraine attack lasting >72 hours
- **Severity**: Debilitating pain
- **Complications**: Dehydration, medication overuse
- **Treatment**: Often requires hospitalization

### Migraine Triggers
- **Hormonal**: Menstruation, oral contraceptives, menopause
- **Dietary**: Alcohol, aged cheese, chocolate, MSG, nitrates
- **Environmental**: Bright lights, loud sounds, strong odors
- **Sleep**: Too little or too much sleep, irregular sleep
- **Stress**: Emotional stress, relaxation after stress
- **Physical**: Weather changes, barometric pressure

## Tension-Type Headache

### Overview
- **Most common**: Primary headache disorder
- **Prevalence**: 30-80% of population
- **Pathophysiology**: Muscle contraction and central sensitization
- **Impact**: Generally less disabling than migraine

### Pathophysiology
- **Peripheral mechanisms**: Pericranial muscle tenderness
- **Central sensitization**: Enhanced pain processing
- **Stress response**: Muscle tension and pain amplification
- **Neurotransmitters**: Serotonin and norepinephrine dysfunction

### Clinical Features
- **Quality**: Pressing, tightening, "band-like"
- **Location**: Bilateral, holocephalic
- **Intensity**: Mild to moderate
- **Duration**: 30 minutes to 7 days
- **Associated symptoms**: Mild photophobia or phonophobia (not both)
- **No aggravation**: Routine physical activity

### Subtypes
- **Episodic infrequent**: <1 day per month
- **Episodic frequent**: 1-14 days per month
- **Chronic**: ≥15 days per month for >3 months

## Cluster Headache

### Overview
- **Prevalence**: 0.1% of population, male predominance (5:1)
- **Pattern**: Attacks occur in clusters with remission periods
- **Severity**: Excruciating pain, often described as worst possible
- **Pathophysiology**: Hypothalamic dysfunction, trigeminal activation

### Pathophysiology
- **Hypothalamic generator**: Posterior hypothalamus activation
- **Circadian rhythms**: Attacks often occur at same time daily
- **Trigeminal-autonomic reflex**: Cranial parasympathetic activation
- **Vascular changes**: Carotid artery dilation

### Clinical Features
- **Pain**: Severe, unilateral, orbital/supraorbital/temporal
- **Quality**: Stabbing, burning, "red-hot poker"
- **Duration**: 15 minutes to 3 hours
- **Frequency**: Every other day to 8 times per day
- **Timing**: Often nocturnal, same time each day
- **Restlessness**: Patients cannot remain still

#### Associated Autonomic Features (Ipsilateral)
- **Conjunctival injection**: Red, watery eye
- **Lacrimation**: Excessive tearing
- **Nasal congestion**: Stuffy nose
- **Rhinorrhea**: Runny nose
- **Ptosis**: Eyelid drooping
- **Miosis**: Pupil constriction
- **Forehead/facial sweating**: Diaphoresis

### Cluster Patterns
- **Episodic**: Clusters last weeks to months, separated by remissions
- **Chronic**: Attacks occur for >1 year without remission >1 month
- **Cluster period**: Typically 4-8 weeks
- **Remission**: Usually 6 months to 2 years

## Secondary Headaches

### Red Flags (Danger Signs)
- **Sudden onset**: "Thunderclap" headache
- **"Worst headache ever": Change in headache pattern
- **Fever and neck stiffness**: Meningitis signs
- **Neurological deficits**: Focal signs, altered consciousness
- **Age factors**: New headache >50 years, <5 years
- **Systemic illness**: Cancer, HIV, pregnancy
- **Trauma**: Recent head injury
- **Exertion**: Headache triggered by cough, exercise, sexual activity

### Common Secondary Causes

#### Intracranial Pressure Changes
- **Increased ICP**: Tumors, hydrocephalus, pseudotumor cerebri
- **Decreased ICP**: Post-lumbar puncture, CSF leak
- **Characteristics**: Positional component, papilledema

#### Vascular Causes
- **Subarachnoid hemorrhage**: Sudden, severe, "thunderclap"
- **Intracerebral hemorrhage**: Focal deficits, altered consciousness
- **Venous thrombosis**: Progressive headache, seizures
- **Arterial dissection**: Neck pain, Horner's syndrome
- **Giant cell arteritis**: Age >50, jaw claudication, ESR elevation

#### Infectious Causes
- **Meningitis**: Fever, neck stiffness, photophobia
- **Encephalitis**: Altered mental status, seizures
- **Brain abscess**: Focal deficits, fever
- **Sinusitis**: Facial pain, nasal congestion

#### Other Secondary Causes
- **Medication overuse**: Analgesic rebound headache
- **Hypertensive crisis**: Severe hypertension, end-organ damage
- **Carbon monoxide poisoning**: Cherry-red skin, altered consciousness
- **Sleep apnea**: Morning headaches, snoring

## Diagnosis

### Clinical History
- **Headache characteristics**: PQRST analysis
  - **P**rovocation/palliation: Triggers, relieving factors
  - **Q**uality: Throbbing, pressing, stabbing
  - **R**egion/radiation: Location, unilateral vs bilateral
  - **S**everity: 1-10 pain scale
  - **T**iming: Onset, duration, frequency, pattern

- **Associated symptoms**: Nausea, vomiting, photophobia, phonophobia, aura
- **Red flags**: Dangerous features requiring immediate evaluation
- **Medication history**: Current and past treatments, overuse
- **Family history**: Migraine, cluster headache
- **Triggers**: Identifiable precipitating factors

### Physical Examination
- **Vital signs**: Blood pressure, temperature, heart rate
- **General examination**: Signs of systemic illness
- **Neurological examination**: Mental status, cranial nerves, motor, sensory, reflexes, coordination
- **Head and neck**: Palpation of muscles, temporal arteries, sinuses
- **Fundoscopy**: Papilledema, hemorrhages

### Diagnostic Criteria

#### Migraine Without Aura (ICHD-3)
A. At least 5 attacks fulfilling criteria B-D
B. Headache attacks lasting 4-72 hours (untreated or unsuccessfully treated)
C. Headache has at least 2 of:
   - Unilateral location
   - Pulsating quality
   - Moderate or severe pain intensity
   - Aggravation by routine physical activity
D. During headache at least 1 of:
   - Nausea and/or vomiting
   - Photophobia and phonophobia
E. Not better accounted for by another ICHD-3 diagnosis

### Neuroimaging

#### Indications for Imaging
- **Red flags**: Sudden onset, neurological deficits, change in pattern
- **Atypical features**: Unusual presentation
- **Treatment failure**: Refractory headaches
- **Age factors**: New headache >50 years

#### Imaging Modalities
- **CT scan**: Emergency evaluation, suspected hemorrhage
- **MRI brain**: Preferred for detailed evaluation
- **MRA/CTA**: Vascular imaging if indicated
- **Lumbar puncture**: If meningitis or SAH suspected with negative CT

### Laboratory Studies
- **ESR/CRP**: If giant cell arteritis suspected (age >50)
- **Complete blood count**: If systemic illness suspected
- **Thyroid function**: Hyperthyroidism can cause headaches
- **CSF analysis**: If infection or SAH suspected

## Treatment

### Migraine Treatment

#### Acute Treatment

##### First-Line Agents
- **NSAIDs**: Ibuprofen 400-800 mg, naproxen 500-1000 mg
- **Acetaminophen**: 1000 mg (less effective than NSAIDs)
- **Triptans**: 5-HT1B/1D agonists
  - **Sumatriptan**: 50-100 mg PO, 6 mg SC, 20 mg nasal
  - **Rizatriptan**: 10 mg PO, rapid onset
  - **Eletriptan**: 40 mg PO, high efficacy
  - **Zolmitriptan**: 2.5-5 mg PO, 5 mg nasal

##### Second-Line Agents
- **Ergotamines**: Ergotamine/caffeine, DHE
- **Antiemetics**: Metoclopramide, prochlorperazine
- **Combination analgesics**: Excedrin (ASA/APAP/caffeine)

##### New Acute Treatments
- **Gepants**: CGRP receptor antagonists
  - **Ubrogepant**: 50-100 mg PO
  - **Rimegepant**: 75 mg PO
- **Ditans**: 5-HT1F agonists
  - **Lasmiditan**: 50-200 mg PO

#### Preventive Treatment

##### Indications
- **Frequency**: ≥4 attacks per month
- **Duration**: Attacks >12 hours
- **Disability**: Significant impact on quality of life
- **Acute treatment failure**: Poor response or contraindications

##### First-Line Preventive Agents
- **Beta-blockers**: Propranolol 80-240 mg/day, metoprolol 100-200 mg/day
- **Antiepileptics**: Topiramate 50-200 mg/day, valproate 500-1500 mg/day
- **Tricyclic antidepressants**: Amitriptyline 10-100 mg/day
- **Calcium channel blockers**: Verapamil 240-480 mg/day

##### Newer Preventive Treatments
- **CGRP monoclonal antibodies**: Monthly or quarterly injections
  - **Erenumab**: 70-140 mg monthly SC
  - **Fremanezumab**: 225 mg monthly or 675 mg quarterly SC
  - **Galcanezumab**: 240 mg loading, then 120 mg monthly SC
  - **Eptinezumab**: 100-300 mg quarterly IV

##### Other Preventive Options
- **Botulinum toxin**: Chronic migraine, 155-195 units every 12 weeks
- **Devices**: Cefaly (supraorbital stimulation), Spring TMS
- **Supplements**: Riboflavin 400 mg/day, CoQ10 300 mg/day, magnesium 400 mg/day

### Tension-Type Headache Treatment

#### Acute Treatment
- **Simple analgesics**: Acetaminophen 1000 mg, aspirin 1000 mg
- **NSAIDs**: Ibuprofen 400-800 mg, naproxen 500 mg
- **Combination products**: Excedrin, Fioricet (avoid frequent use)

#### Preventive Treatment
- **Tricyclic antidepressants**: Amitriptyline 10-75 mg/day
- **SSRIs**: If comorbid depression
- **Muscle relaxants**: Tizanidine for muscle tension
- **Topiramate**: 50-200 mg/day for chronic TTH

### Cluster Headache Treatment

#### Acute Treatment
- **High-flow oxygen**: 100% oxygen 12-15 L/min for 15-20 minutes
- **Sumatriptan**: 6 mg SC (most effective)
- **Zolmitriptan**: 5-10 mg nasal spray
- **DHE**: Dihydroergotamine nasal spray

#### Preventive Treatment
- **Verapamil**: 240-960 mg/day (first-line)
- **Lithium**: 600-1200 mg/day (monitor levels)
- **Topiramate**: 100-200 mg/day
- **Corticosteroids**: Prednisone for cluster termination

#### Transitional Treatment
- **Prednisone**: 60-80 mg/day, rapid taper over 2-3 weeks
- **Greater occipital nerve block**: Steroid injection
- **DHE protocol**: Hospital-based treatment

### Non-Pharmacological Treatments

#### Behavioral Interventions
- **Relaxation training**: Progressive muscle relaxation
- **Biofeedback**: EMG, thermal, HRV biofeedback
- **Cognitive behavioral therapy**: Coping strategies, stress management
- **Stress management**: Mindfulness, meditation

#### Lifestyle Modifications
- **Sleep hygiene**: Regular sleep schedule, 7-8 hours
- **Exercise**: Regular aerobic exercise
- **Diet**: Avoid triggers, regular meals
- **Hydration**: Adequate fluid intake
- **Trigger avoidance**: Identify and avoid personal triggers

#### Physical Therapies
- **Massage therapy**: Muscle tension relief
- **Acupuncture**: Evidence for migraine prevention
- **Physical therapy**: Posture correction, neck exercises
- **Chiropractic**: Limited evidence

### Device Therapies
- **Transcutaneous supraorbital neurostimulation**: Cefaly device
- **Transcranial magnetic stimulation**: Spring TMS
- **Noninvasive vagus nerve stimulation**: gammaCore
- **Remote electrical neuromodulation**: Nerivio

## Medication Overuse Headache

### Overview
- **Definition**: Headache on ≥15 days/month due to overuse of acute medications
- **Risk factors**: Frequent headache, anxiety, depression
- **Medications**: Analgesics, triptans, ergotamines, combination products
- **Pathophysiology**: Central sensitization, medication dependence

### Clinical Features
- **Daily or near-daily headaches**: Often present upon awakening
- **Rebound pattern**: Headache returns as medication wears off
- **Medication escalation**: Increasing frequency and dose
- **Reduced efficacy**: Decreased response to preventive medications

### Treatment
- **Medication withdrawal**: Discontinue overused medication
- **Bridge therapy**: Short course of corticosteroids or DHE
- **Preventive medication**: Start appropriate prophylaxis
- **Support**: Patient education, behavioral interventions

## Special Populations

### Pediatric Headaches
- **Prevalence**: Increases with age, equal gender distribution until puberty
- **Differences**: Shorter duration, bilateral location, prominent nausea
- **Treatment**: Age-appropriate dosing, avoid certain medications
- **School impact**: Significant absenteeism and disability

### Headaches in Women

#### Menstrual Migraine
- **Pattern**: Attacks related to menstrual cycle
- **Pathophysiology**: Estrogen withdrawal
- **Treatment**: Extended-cycle oral contraceptives, triptans, NSAIDs

#### Pregnancy and Headaches
- **Migraine changes**: Often improves during pregnancy
- **Safe medications**: Acetaminophen, limited use of certain medications
- **Avoid**: Ergotamines, high-dose aspirin, most preventive medications
- **Secondary causes**: Preeclampsia, cortical vein thrombosis

#### Menopause
- **Hormone changes**: May worsen or improve migraines
- **Hormone replacement**: Estrogen may help or worsen headaches
- **Treatment considerations**: Age-related comorbidities

### Elderly Patients
- **New onset headache**: Higher concern for secondary causes
- **Giant cell arteritis**: Important consideration in >50 years
- **Medication considerations**: Drug interactions, side effects
- **Comorbidities**: Cardiovascular disease, cognitive impairment

## Complications

### Acute Complications
- **Status migrainosus**: Prolonged migraine >72 hours
- **Medication overuse headache**: From frequent acute medication use
- **Dehydration**: From vomiting, poor oral intake
- **Psychiatric complications**: Depression, anxiety, suicide risk

### Chronic Complications
- **Chronic daily headache**: Transformation to daily pattern
- **Disability**: Work absence, reduced productivity
- **Medication side effects**: Long-term medication use
- **Relationship impact**: Family and social consequences

### Rare Complications
- **Migrainous infarction**: Stroke during migraine with aura
- **Persistent aura**: Prolonged neurological symptoms
- **Seizures**: Associated with hemiplegic migraine
- **Chronic paroxysmal hemicrania**: Similar to cluster headache

## Prognosis

### Migraine
- **Natural history**: Often begins in adolescence, peaks in 30s-40s
- **Women**: May improve after menopause
- **Men**: More stable course
- **Chronic migraine**: 2.5% annual incidence from episodic migraine
- **Remission**: Possible, especially in later life

### Tension-Type Headache
- **Course**: Usually stable, may fluctuate with stress
- **Chronic form**: More persistent, harder to treat
- **Prognosis**: Generally good with appropriate management

### Cluster Headache
- **Episodic form**: May have prolonged remissions
- **Chronic form**: 10-15% of patients, continuous pattern
- **Age factors**: May "burn out" in older age
- **Treatment response**: Generally good with appropriate therapy

### Factors Affecting Prognosis
- **Early treatment**: Better outcomes with prompt intervention
- **Lifestyle factors**: Sleep, exercise, stress management
- **Comorbidities**: Depression, anxiety affect prognosis
- **Medication adherence**: Critical for preventive treatment success

## Key Points

- Primary headaches (migraine, tension-type, cluster) account for >95% of all headaches
- Red flag symptoms require immediate evaluation for secondary causes
- Migraine is a neurovascular disorder with genetic and environmental factors
- Triptans are first-line acute treatment for moderate-severe migraine
- CGRP-targeted therapies represent major advances in migraine prevention
- Cluster headache requires specific treatments including high-flow oxygen
- Medication overuse headache is a common complication of frequent analgesic use
- Non-pharmacological approaches are important adjuncts to medical treatment
- Lifestyle modifications and trigger avoidance can reduce headache frequency
- Chronic headaches significantly impact quality of life and require comprehensive management

## References

1. Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1-211.
2. Dodick DW. Migraine. Lancet. 2018;391(10127):1315-1330.
3. Ashina M, Hansen JM, Do TP, Melo-Carrillo A, Burstein R, Moskowitz MA. Migraine and the trigeminovascular system-40 years and counting. Lancet Neurol. 2019;18(8):795-804.